Sight Sciences, Inc. — Company profile
Healthcare · Medical Devices · United States
Last price 9.32 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 513.42M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Details
| Name | Sight Sciences, Inc. |
| Sector | Healthcare |
| Industry | Medical Devices |
| Employees | 186 |
| Founded | 2011 |
| Ipo Date | 2021-07-15 |
| Ceo | Paul Badawi |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 24.00 |
| Isin | US82657M1053 |
| Cusip | 82657M105 |
| Cik | 1531177 |
| Sic | 3841 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Paul Badawi | Co-Founder, President, Chief Executive Officer and Director |
| Alison Perry Bauerlein | Chief Operating Officer |
| Dr. David Badawi M.D. | Co-Founder, Chief Technology Officer and Director |
| James Rodberg | Chief Financial Officer and Treasurer |
| Steve R. Tamayo Jr. | Vice President and Chief Ethics and Compliance Officer |
| Kashif Rashid J.D. | Chief Legal Officer and Corporate Secretary |
| Kelly Vaupel | Vice President of Marketing and Commercial Strategy, Interventional Glaucoma |
| Sonia Clark | Vice President of People |
| Brenton Taylor | Executive Vice President of Operations and Research & Development |
| Kelly Petrucci | Senior Vice President of Market Access and Strategy |
Contact
| Address | 4040 Campbell Avenue, Suite 100, Menlo Park, California 94025, United States |
| Phone | 877 266 1144 |
| Website | https://www.sightsciences.com |